FDA Grants Priority Review for Tecentriq Supplement Application
The FDA has granted priority review for the supplemental application of Tecentriq (atezolizumab) submitted by Genentech.
Therapeutic Area
Therapeutic area intelligence for PD-L1 Inhibitor with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.